Zhejiang Huahai Pharmaceutical (SHA:600521) said the HB0017 injection's phase III clinical trial met the primary and secondary efficacy endpoints, according to a Shanghai bourse filing on Thursday.
The drug is being tested as a treatment for psoriasis, with 408 patients enrolled for the trial.
The drug, which was developed by subsidiary Shanghai Huaota Biopharmaceutical, showed safety and tolerability on patients during the trial.
The pharmaceutical company invested 372.1 million yuan into the research and development of the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments